Clinical trial · Interventional
A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC
A Randomized Phase II Study of Adebrelimab in Combination with Chemotherapy with or Without Bevacizumab Neoadjuvant Therapy for Resectable Non-Squamous Non-Small Cell Lung Cancer
NCT06775275CI-TRIAL-00084694recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective, multicenter, randomized, uncontrolled Phase II study to assess the efficacy and safety of adebrelimab in combination with chemotherapy with or without bevacizumab for the treatment of resectable Stage II-IIIB (T3N2) NSQ-NSCLC and to explore biomarkers associated with efficacy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Resectable Lung Non-Small Cell Carcinoma | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Adebellizumab | Drug | — | UNRESOLVED |
| Bevacizumab | Drug | Bevacizumab | ALIAS |
| Platinum-based chemotherapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- four-drug combination group
- description
- PD-L1 inhibitor with chemotherapy with Antiangiogenic therapy for neoadjuvant therapy
- interventionNames
- Drug: Adebellizumab
- Drug: Bevacizumab
- Drug: Platinum-based chemotherapy
- type
- EXPERIMENTAL
- label
- three-drug combination group
- description
- PD-L1 inhibitor with chemotherapy for neoadjuvant therapy
- interventionNames
- Drug: Adebellizumab
- Drug: Platinum-based chemotherapy
Primary outcomes (1)
- measure
- Pathological complete response
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Resectable NSQ NSCLC * Age 18-65 years * male or female * ECOG 0-1 * Subjects have not received surgery, chemotherapy, radiotherapy and biological treatment of treatment-naive non-squamous non-small cell lung cancer * Subjects must have adequate pulmonary function for the intended pneumonectomy; Exclusion Criteria: * SCLC or SQ NSCLC * previously used anti-PD1, anti-PDL1, anti-CTLA4 antibodies, etc. * patients who have previously used anti-angiogenic drugs; * allergic to any component of the study drug or chemotherapy drugs * patients with any severe and or uncontrolled disease
References
Publications (0)
Data not yet available
No reference posted for this study.